PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Kurt Schalper, MD, PhD - Leveraging Biomarkers to Guide Candidate Selection for Cancer Immunotherapies: Precision is Paramount, Collaboration is Crucial
Go online to PeerView.com/Precision20?Promocode=860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, it has become clear that reliable biomarkers are needed to guide clinical decisions regarding treatment selection and identification of patients who are most likely to benefit from specific agents or immune-based combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, and others. Testing for these biomarkers has significant implications for pathology practice. This PeerView Live Seminars and Tumor Board symposium will provide participating pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminars segments, our expert panel will review evidence on current and emerging immunotherapies and biomarkers, and the Tumor Board will focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals in interpreting biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Characterize the efficacy/safety profiles and clinical roles of current and emerging immunotherapies and combinations across different malignancies, along with relevant biomarker alignments, Evaluate the latest evidence supporting the use of PD-L1, MSI/MMR, TMB, and other emerging biomarkers and multiparametric approaches as predictors of benefit from cancer immunotherapies, Discuss the practical aspects of immunotherapy biomarker testing and interpretation in pathology practice, including companion diagnostic use requirements, benefits/limitations of different testing methodologies, assays, cutpoints, and other nuances, Implement best practices for cancer immunotherapy biomarker testing and interpretation in collaboration with oncologists and other relevant professionals to guide and refine the use of cancer immunotherapies in current practice